New global initiative urges patients and clinicians to wait for biomarker testing results before starting treatment.

Dr. Elena Elimova discusses how Ziihera-based therapy may change treatment for HER2+ locally advanced or metastatic ...

The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid ...

New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx ...

LUND, SE / ACCESS Newswire / January 9, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today ...

GLP-1 receptor agonists may be superior to aspirin for primary prevention of colorectal cancer, according to study results ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...

ASCO GU 2025 had groundbreaking advancements in genitourinary cancer treatments, focusing on prostate cancer, renal cell ...

Zanidatamab plus chemotherapy delays progression or death in patients with untreated locally advanced or metastatic gastroesophageal adenocarcinoma.

Cancer survivors can be a source of hope for others navigating life with cancer. Survivors include anyone who has been ...

AI innovations, such as the ASCO Guidelines Assistant, enhance evidence-based decision-making by providing quick access to critical guidelines. ASCO 2025 highlighted breakthroughs, including improved ...